Research programme: DTaP vaccine - Serum Institute of India

Drug Profile

Research programme: DTaP vaccine - Serum Institute of India

Alternative Names: Acellular pertusis vaccines - Serum Institute of India; Diphtheria tetanus-acellular pertussis vaccine - Serum Institute of India

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Serum Institute of India
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Pertussis

Most Recent Events

  • 30 Nov 2016 Genticel has patent protection for GTL 003 in USA
  • 02 Feb 2015 Research programme: DTaP vaccine - Serum Institute of India is available for licensing in (excluding USA, Canada, New Zealand, Australia, Japan, Israel, Turkey, Europe) as of 02 Feb 2015.
  • 02 Feb 2015 Preclinical trials in Pertussis in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top